| Amy L Eberle, | |
|
3433 Nw 56th St Ste 400, Oklahoma City, OK 73112-4430 | |
| (405) 947-3341 | |
| (405) 951-4358 |
| Full Name | Amy L Eberle |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist |
| Location | 3433 Nw 56th St Ste 400, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457825432 | NPI | - | NPPES |
| 87638 | Other | OK | OKLAHOMA LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 87638 (Oklahoma) | Primary |
| Entity Name | Midwest Hospital Medicine Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124388855 PECOS PAC ID: 4880841618 Enrollment ID: O20120829000397 |
News Archive
A study published in the American Journal of Preventive Medicine sheds new light on the sharp rise in fatal drug overdoses in recent years, one of the most severe public health challenges of our time. The study found that the growth in fatal overdoses for non-Hispanic whites aged 22-56 years was sufficiently large to account for the entire growth in mortality rates and years of potential life lost (YPLL) for this population from 1999 to 2015.
In a radical departure from established treatment protocols, Dr. Mark Basik, a surgical oncologist at Segal Cancer Centre at the Jewish General Hospital and senior investigator at the Lady Davis Institute, is leading an international effort that will lead to a clinical trial to forego surgery in breast cancer patients who show no signs of residual cancer following a course of pre-operative chemotherapy.
A technique called distraction osteogenesis can create increased length of the upper jaw in patients with cleft lip and palate deformities, reports a study in the March issue of The Journal of Craniofacial Surgery, edited by Mutaz B. Habal, MD, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
A team of researchers at the University of Cambridge has identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication.
Scientists at Texas Biomedical Research Institute (Texas Biomed) today announced the launch of a comprehensive research initiative to investigate multiple animal species and their response to the novel coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Ou Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528642642 PECOS PAC ID: 5991105876 Enrollment ID: O20210615000618 |
News Archive
A study published in the American Journal of Preventive Medicine sheds new light on the sharp rise in fatal drug overdoses in recent years, one of the most severe public health challenges of our time. The study found that the growth in fatal overdoses for non-Hispanic whites aged 22-56 years was sufficiently large to account for the entire growth in mortality rates and years of potential life lost (YPLL) for this population from 1999 to 2015.
In a radical departure from established treatment protocols, Dr. Mark Basik, a surgical oncologist at Segal Cancer Centre at the Jewish General Hospital and senior investigator at the Lady Davis Institute, is leading an international effort that will lead to a clinical trial to forego surgery in breast cancer patients who show no signs of residual cancer following a course of pre-operative chemotherapy.
A technique called distraction osteogenesis can create increased length of the upper jaw in patients with cleft lip and palate deformities, reports a study in the March issue of The Journal of Craniofacial Surgery, edited by Mutaz B. Habal, MD, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
A team of researchers at the University of Cambridge has identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication.
Scientists at Texas Biomedical Research Institute (Texas Biomed) today announced the launch of a comprehensive research initiative to investigate multiple animal species and their response to the novel coronavirus disease (COVID-19).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy L Eberle, 5401 N Portland Ave Ste 410, Oklahoma City, OK 73112-2131 Ph: (405) 604-4202 | Amy L Eberle, 3433 Nw 56th St Ste 400, Oklahoma City, OK 73112-4430 Ph: (405) 947-3341 |
News Archive
A study published in the American Journal of Preventive Medicine sheds new light on the sharp rise in fatal drug overdoses in recent years, one of the most severe public health challenges of our time. The study found that the growth in fatal overdoses for non-Hispanic whites aged 22-56 years was sufficiently large to account for the entire growth in mortality rates and years of potential life lost (YPLL) for this population from 1999 to 2015.
In a radical departure from established treatment protocols, Dr. Mark Basik, a surgical oncologist at Segal Cancer Centre at the Jewish General Hospital and senior investigator at the Lady Davis Institute, is leading an international effort that will lead to a clinical trial to forego surgery in breast cancer patients who show no signs of residual cancer following a course of pre-operative chemotherapy.
A technique called distraction osteogenesis can create increased length of the upper jaw in patients with cleft lip and palate deformities, reports a study in the March issue of The Journal of Craniofacial Surgery, edited by Mutaz B. Habal, MD, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
A team of researchers at the University of Cambridge has identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication.
Scientists at Texas Biomedical Research Institute (Texas Biomed) today announced the launch of a comprehensive research initiative to investigate multiple animal species and their response to the novel coronavirus disease (COVID-19).
› Verified 2 days ago
Jamie Louise Hunt, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young, Andrews Academic Tower, Suite 8400, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 405-271-5892 | |
Mrs. Janet Elizabeth Kristic, APRN CLINICAL NURSE Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1117 Nw 50th, Oklahoma City, OK 73118 Phone: 405-842-4435 Fax: 405-842-2846 | |
Todd J Ramer, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4300 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-752-3539 | |
Andrea Jeanne Mccoy, R.N. Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4050 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-608-3800 Fax: 405-608-3838 | |
Shanelle Stensaas, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-613-3351 | |
Leighann Fullagar, APRN-CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-713-7403 Fax: 405-713-2794 | |
Michelle Tull, ACNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 800 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-3402 |